Enzyme inhibitors for metabolic redirection
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 6, 2004
Grant Date -
N/A
app pub date -
Dec 13, 2000
filing date -
Feb 23, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method is described for improving the pharmacokinetics of a drug in a subject, by co-administering oligomers, preferably PMO's (phosphorodiamidate morpholino oligonucleotides), antisense to RNAs encoding drug-metabolizing enzymes, particularly p450 enzymes. The oligomers reduce production of the drug-metabolizing enzymes, which extends drug half-life and effectiveness and/or decreases drug toxicity.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully